Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report

In advanced lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutation, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have an excellent and long-lasting therapeutic response; however, virtually all patients eventually develop drug resistance and expe...

Full description

Bibliographic Details
Main Authors: Shubin Chen, Qitao Yu, Wei Jiang, Yukun Lu, Yun Zhao, Huilin Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Medicine
Subjects:
advanced lung adenocarcinoma
EGFR exon 19 deletion
immunotherapy
EGFR-TKI
rechallenge
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1168220/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1168220/full

Similar Items